Bank of New York Mellon’s Kura Oncology KURA Stock Holding History

Bank of New York Mellon’s Portfolio KURA Stock Details KURA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.83M	Buy	257,767 +3,442	+1%	+$32.5K	﹤0.01%	2753
2026 Q1	$2.07M	Sell	254,325 -4,102	-2%	-$35.2K	﹤0.01%	2793
2025 Q4	$2.69M	Buy	258,427 +3,187	+1%	+$33.4K	﹤0.01%	2674
2025 Q3	$2.26M	Buy	255,240 +16,733	+7%	+$119K	﹤0.01%	2734
2025 Q2	$1.38M	Buy	238,507 +37,695	+19%	+$231K	﹤0.01%	2938
2025 Q1	$1.33M	Sell	200,812 -2,129	-1%	-$16.6K	﹤0.01%	2896
2024 Q4	$1.77M	Sell	202,941 -2,737	-1%	-$39.4K	﹤0.01%	2811
2024 Q3	$4.02M	Sell	205,678 -50,219	-20%	-$1.02M	﹤0.01%	2401
2024 Q2	$5.27M	Buy	255,897 +11,212	+5%	+$230K	﹤0.01%	2325
2024 Q1	$5.22M	Sell	244,685 -16,104	-6%	-$313K	﹤0.01%	2309
2023 Q4	$3.75M	Sell	260,789 -955	-0.4%	-$9.39K	﹤0.01%	2512
2023 Q3	$2.39M	Buy	261,744 +25,677	+11%	+$261K	﹤0.01%	2707
2023 Q2	$2.5M	Buy	236,067 +10,516	+5%	+$124K	﹤0.01%	2716
2023 Q1	$2.76M	Sell	225,551 -5,114	-2%	-$63.8K	﹤0.01%	2615
2022 Q4	$2.86M	Buy	230,665 +2,004	+0.9%	+$29.1K	﹤0.01%	2650
2022 Q3	$3.12M	Buy	228,661 +21,821	+11%	+$337K	﹤0.01%	2560
2022 Q2	$3.79M	Sell	206,840 -24,813	-11%	-$357K	﹤0.01%	2468
2022 Q1	$3.72M	Buy	231,653 +812	+0.4%	+$11.7K	﹤0.01%	2576
2021 Q4	$3.23M	Sell	230,841 -24,230	-9%	-$393K	﹤0.01%	2703
2021 Q3	$4.78M	Buy	255,071 +36,351	+17%	+$685K	﹤0.01%	2512
2021 Q2	$4.56M	Sell	218,720 -79,622	-27%	-$1.98M	﹤0.01%	2541
2021 Q1	$8.43M	Buy	298,342 +12,746	+4%	+$403K	﹤0.01%	2188
2020 Q4	$9.33M	Buy	285,596 +43,007	+18%	+$1.51M	﹤0.01%	2042
2020 Q3	$7.43M	Buy	242,589 +35,696	+17%	+$788K	﹤0.01%	2009
2020 Q2	$3.37M	Buy	206,893 +57,065	+38%	+$823K	﹤0.01%	2411
2020 Q1	$1.49M	Buy	149,828 +4,919	+3%	+$56.3K	﹤0.01%	2704
2019 Q4	$1.99M	Buy	144,909 +3,821	+3%	+$56.6K	﹤0.01%	2820
2019 Q3	$2.14M	Buy	141,088 +19,436	+16%	+$346K	﹤0.01%	2722
2019 Q2	$2.4M	Sell	121,652 -414	-0.3%	-$6.87K	﹤0.01%	2711
2019 Q1	$2.02M	Buy	122,066 +593	+0.5%	+$9.14K	﹤0.01%	2771
2018 Q4	$1.71M	Buy	121,473 +9,218	+8%	+$122K	﹤0.01%	2809
2018 Q3	$1.97M	Buy	112,255 +9,884	+10%	+$189K	﹤0.01%	2842
2018 Q2	$1.86M	Buy	102,371 +19,072	+23%	+$323K	﹤0.01%	2887
2018 Q1	$1.56M	Buy	83,299 +16,363	+24%	+$319K	﹤0.01%	2955
2017 Q4	$1.02M	Buy	66,936 +7,655	+13%	+$113K	﹤0.01%	3234
2017 Q3	$886K	Buy	59,281 +28,031	+90%	+$263K	﹤0.01%	3295
2017 Q2	$291K	Buy	+31,250	New	+$284K	﹤0.01%	3828

Other funds holding KURA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

NFT

Nan Fung Trinity Central, Hong Kong, Hong Kong $1.01B AUM 64.38% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

JAM

Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return

1CM

1492 Capital Management Milwaukee, Wisconsin $339M AUM 120.53% 1-Year Est. Return

IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return

OAM

OP Asset Management Helsinki $9.38B AUM 42.35% 1-Year Est. Return

Bank of New York Mellon's KURA Position: Q2 2026 in Review

Bank of New York Mellon increased its Kura Oncology (KURA) stake by 1.4% in Q2 2026, buying an estimated $32.5K and bringing the position to 257,767 shares worth $2.83M. The position accounts for ﹤0.01% of the portfolio, ranked #2753.

Bank of New York Mellon first reported a position in KURA in Q2 2017 and has held it in 37 quarters since. The position peaked at $9.33M in Q4 2020. 98 funds tracked by Wall St. Rank hold KURA as of Q2 2026.

Bank of New York Mellon held 257,767 shares of Kura Oncology worth $2.83M as of Q2 2026.
Bank of New York Mellon bought 3,442 Kura Oncology shares in Q2 2026, an estimated $32.5K.
Kura Oncology made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #2753 holding.
Bank of New York Mellon first reported a position in Kura Oncology in Q2 2017 and has held it in 37 quarters since.
Bank of New York Mellon's Kura Oncology position peaked at $9.33M in Q4 2020.
98 funds tracked by Wall St. Rank held Kura Oncology as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.